Brexucabtagene autoleucel therapy induces complete remission in a primary refractory blastoid mantle cell lymphoma with neurolymphomatosis

Am J Hematol. 2021 Aug 1;96(8):E298-E301. doi: 10.1002/ajh.26233. Epub 2021 May 29.

Authors

Arushi Khurana¹, Joanna C Dalland², Jason R Young³, David J Inwards¹, Jonas Paludo¹

Affiliations

¹ Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
² Department of Laboratory Medicine and Pathology, Division of Hematopathology, Mayo Clinic, Rochester, Minnesota, USA.
³ Department of Radiology, Division of Nuclear Medicine, Mayo Clinic, Rochester, Minnesota, USA.

PMID: 33984157
DOI: 10.1002/ajh.26233

No abstract available

Publication types

Letter

MeSH terms

Humans
Lymphoma, Mantle-Cell / drug therapy*
Male
Middle Aged
Neurolymphomatosis / drug therapy*
Receptors, Chimeric Antigen / therapeutic use*

Substances

Receptors, Chimeric Antigen